Skip to Content

'
Wai-Kwan Alfred Yung, M.D.

Present Title & Affiliation

N/A

Education & Training

Degree-Granting Education

1975 University of Chicago, Pritzker School of Medicine, Chicago, IL, MD, Medicine
1971 University of Minnesota, Minneapolis, MN, BS, Summa Cum Laude, Biochemistry

Postgraduate Training

1/1979-1/1981 Clinical Fellowship, Neurology, New York Hospital, New York, NY
1/1978-1/1981 Clinical Fellowship, Neuro-Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
1/1978-1/1979 Chief Resident in Neurology, Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY
1/1978-12/1978 Assistant Resident in Neurology, Neurology, University of California, San Diego, CA
1/1976-1/1978 Clinical Residency, Neurology, University of California, San Diego, CA
1/1975-1/1976 Clinical Internship, Neurology, University of California, San Diego, CA

Board Certifications

1/1980 American Board of Psychiatry and Neurology

Experience/Service

Academic Appointments

Professor, Department of Neuro-Oncology, Division of Cancer Medicine, UT M. D. Anderson Cancer Center, Houston, TX, 1992-present

Administrative Appointments/Responsibilities

Department Chair, Department of Neuro-Oncology, Division of Cancer Medicine, UT M. D. Anderson Cancer Center, Houston, TX, 2002-present

Honors and Awards

2007-present The Cancer Genome Atlas, NIH/NCI
2006-present Editor-in-Chief, Neuro-Oncology
1992-present Best Doctors in America

Selected Publications

Peer-Reviewed Original Research Articles
1. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD. Phase II study of imatinib mesylate (Gleevec(R)) for recurrent meningiomas (North American Brain Tumor Consortium Study 01-08). Neuro Oncol, 3/17/2009. e-Pub 3/17/2009. PMID: 19293394.
2. Groves MD, Hess KR, Puduvalli VK, Colman H, Conrad CA, Gilbert MR, Weinberg J, Cristofanilli M, Yung WKA, Liu TJ. Biomarkers of Disease: Cerebrospinal fluid Vascular Endothelial Growth factor (VEGF) and Stromal cell derived factor (SDF-1) levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. Journal of Neuro-Oncology. e-Pub 3/2009. PMID: 19267183.
3. Powis G, Ihle NT, Yung WK. Inhibiting PI-3-K for glioma therapy. Cell Cycle 8(3). e-Pub 2/1/2009. PMID: 19164951.
4. Freire P, Vilela M, Deus H, Kim YW, Koul D, Colman H, Aldape KD, Bogler O, Yung WK, Coombes K, Mills GB, Vasconcelos AT, Almeida JS. Exploratory analysis of the copy number alterations in glioblastoma multiforme. PLoS One 3(12). e-Pub 12/30/2008. PMCID: PMC2605252.
5. Yung WK. Moving toward the next steps in angiogenesis therapy? Neuro Oncol 10(6):939, 12/2008. e-Pub 11/3/2008. PMID: 18981258.
6. Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, Bekele BN, Yung WK. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol 10(6):940-5, 12/2008. e-Pub 8/2008. PMID: 18708344.
7. de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol 90(1):89-97, 10/2008. e-Pub 6/2008. PMID: 18581057.
8. de Groot JF, Yung WK. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 14(5):279-85, Sep-Oct, 9/2008. PMID: 18836331.
9. Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Wen PY, Fine HA, Mehta MP, DeAngelis LM, Lieberman FS, Cloughesy TF, Robins HI, Abrey LE, Prados MD, Prados MD. Neuro-Oncology clinical trial design for targeted therapies -- Lessons learned from the North American Brain Tumor Consortium. Neuro Oncol 10(4):631-642, 8/2008. e-Pub 6/17/2008. PMCID: PMC2666238.
10. Prados MD, Yung WKA, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J.. Phase I trial of gefitinib and temozolomide in patients with malignant gliomas: A North American Brain Tumor Consortium Study. Cancer Chemother Pharmacol 61((6)):1059-1067, 5/2008. e-Pub 8/2007. PMID: 17694310.
11. Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Formad AD, Puduvallil VP, Colman HC, Hess KR, Yung WKA. A multicenter Phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 10(2):208-215, 4/2008. e-Pub 3/3/2008. PMCID: PMC2613823.
12. Puduvalli VK, Giglio P, Groves MD, Hess K, Gilbert MR, Mahankali S, Jackson E, Levin V, Conrad CA, Hsu S, Colman H, deGroot J, Ritterhouse MG, Ictech S, Yung WKA. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol 10(2):216-222, 4/2008. e-Pub 2/26/2008. PMCID: PMC2613824.
13. Lamborn KR, Yung WKA, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD.. Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10(2):162-170, 4/2008. e-Pub 3/4/2008. PMCID: PMC2613818.
14. deGroot JF, Piao Y, Lu L, Fuller Gn, Yung WK. Knockdown of GluR1 expression by RNA interference inhigits glioma proliferation. J Neurooncol 88(2):121-33, 3/2008. e-Pub 3/2008. PMID: 18317690.
15. Alonso MM, Gomez-Manzano C, Jiang H, Bekele NB, Piao Y, Yung WK, Alemany R, Fueyo J. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 14(8):756-61, 6/2007. e-Pub 6/8/2007. PMID: 17557108.
16. Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, Deangelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 81(3)(3):271-7, 2/2007. e-Pub 9/2006. PMID: 17031561.
17. Koul D, Shen R, Shishodia S, Takada Y, Bhat KP, Reddy SA, Aggarwal BB, Yung WK. PTEN down regulates AP-1 and targets c-fos in human glioma cells Via PI3-kinase/Akt pathway. Mol Cell Biochem 300(1-2)(1-2):77-87, 1/2007. e-Pub 1/2007. PMID: 17235455.
18. Liu JL, Mao Z, LaFortune TA, Alonso MM, Gallick GE, Fueyo J, Yung WK. Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res 67:(22):11054-63, 2007. PMID: 18006852.
19. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prado M, Chang SM, Barker FG 2nd, Buckner JC, James CD, Aldape K. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 1:25(16)(16):2288-2294, 2007. PMID: 17538175.
20. Lee OH, Fueyo J, Xu J, Yung WK, Lemoine MG, Lang FF, Bekele BN, Zhou X, Alonso MA, Aldape KD, Fuller GN, Gomez-Manzano C. Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia 8(5)(5):419-28, 5/2006. PMCID: PMC1592446.
21. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J, Kuhn J. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol 8(2):189-93, 4/2006. e-Pub 3/13/2006. PMCID: PMC1871932.
22. Levin VA, Phuphanich S, Yung WKA, Forsyth PA, Maestro RD, Perry JR, Fuller Gn, Elliot M, Baillet M. Randomized, double-blind, placebo controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 78(3)(3):295-302, 4/2006. e-Pub 4/25/2006. PMID: 16636750.
23. Prados MD, Lamborn K, Yung WKA, Jaeckle K. Rogbins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K. Hess K. Kuhn J. A phase 2 trial of irinotecan (CPT-11) in patietns with recurrent malignant glioma: A North American Brain Tumor Consortium Study. Neuro-Oncology 8:189-93, 2006.
24. Koul D, Shen R, Bergh S, Sheng X, Shishodia S, LaFortune T, Liu Y, deGroot J, Mills GB, Yung WK. Inhibition of Akt survival pathway by a small molecule inhibitor in human glioblastoma. Mol Cancer Ther 5(3)(3):637-44, 2006. PMID: 16546978.

Grant & Contract Support

Title: SPORE in Brain Cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 10/1/2008 - 9/30/2013
 
Title: Collaborative Ependymoma Research Network (CERN)
Funding Source: Collaborative Medical Research Foundation
Role: Co-Investigator
Principal Investigator: Gilbert, Mark R.
Duration: 4/20/2007 - 7/19/2012
 
Title: Smart Bomb Project
Funding Source: Marcus Foundation
Role: Project Leader
Principal Investigator: Robert Bast, M.D.
Duration: 7/10/2006 - 7/9/2009
 
Title: Deciphering synergistic combinatorial targets in glioblastoma
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 7/1/2006 - 6/30/2011
 
Title: Radiation Therapy Oncology Group
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 1/1/2004 - 12/31/2008
 
Title: NABTC Central Operation Grant - Data Management Core
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 1/1/2004 - 12/31/2008
 
Title: NABTC Clinical Center
Funding Source: NIH/NCI
Role: Investigator
Principal Investigator: Mark R. Gilbert, M.D.
Duration: 2/7/1998 - 12/31/2008
 
Title: Cancer Center Support Grant
Funding Source: NIH/NCI
Role: Program Leader
Principal Investigator: John Mendelsohn, M.D.
Duration: 7/1/1978 - 6/30/2013

Last updated: 8/28/2009